Evidence map›Paper›PMID 27121253›Full record

Observational studyInternational journal of obesity (2005)2016

Reduced circulating levels of sTWEAK are associated with NAFLD and may affect hepatocyte triglyceride accumulation.

J Lozano-Bartolomé, G Llauradó, M M Rodriguez, J M Fernandez-Real, J F Garcia-Fontgivell, J Puig, E Maymó-Masip, J Vendrell, M R Chacón

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of obesity (2005), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Frontiers in pharmacology · 2018
    Article
  9. Review
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

J Lozano-BartoloméJoan XXIII University Hospital, IISPV, Tarragona, Spain.
G LlauradóCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Madrid, Spain.
M M RodriguezDepartment of Diabetes, Endocrinology and Nutrition, IdIBGi, CIBERObn, Girona, Spain.
J M Fernandez-RealDepartment of Diabetes, Endocrinology and Nutrition, IdIBGi, CIBERObn, Girona, Spain.
J F Garcia-FontgivellPathology Department, Joan XXIII University Hospital, Tarragona, Spain.
J PuigDepartment of Radiology (IDI), Girona Biomedical Research Institute (IDIBGI), Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain.
E Maymó-MasipJoan XXIII University Hospital, IISPV, Tarragona, Spain.
J VendrellJoan XXIII University Hospital, IISPV, Tarragona, Spain.
M R ChacónJoan XXIII University Hospital, IISPV, Tarragona, Spain.
Institut d'Investigació Sanitària Pere Virgili · ESCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESInstitut d'Investigació Biomèdica de Girona · ESHospital Universitari Joan XXIII de Tarragona · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextNon-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and is strongly associated with obesity, dyslipidaemia and altered glucose regulation. Previous data demonstrated that low circulating levels of tumour necrosis factor weak inducer of apoptosis (sTWEAK) were associated with obesity, diabetes and insulin resistance, all traits associated with an increased risk of NALFD. Circulating sTWEAK levels are expected to be reduced in the presence of NAFLD.

objectiveWe aimed to explore the relationship between NAFLD and circulating sTWEAK levels in obese patients, and to evaluate the effect of sTWEAK on hepatocyte triglyceride accumulation.Design setting and patients:This is an observational case-control study performed in n=112 severely obese patients evaluated for NAFLD by abdominal ultrasound and n=32 non-obese patients without steatosis. Serum sTWEAK concentrations were measured by ELISA. Multivariable analyses were performed to determine the independent predictors of NAFLD. We analysed TWEAK and Fn14 protein expression in liver biopsies by western blotting and immunohistochemistry. An immortalized primary human hepatocyte cell line (HHL) was used to evaluate the effect of sTWEAK on triglyceride accumulation.

resultsWe observed a reduction in serum circulating sTWEAK concentrations with the presence of liver steatosis. On multivariable analysis, lower sTWEAK concentrations were independently associated with the presence of NAFLD (odds ratio (OR)=0.023; 95% confidence interval: 0.001-0.579; P<0.022). In human hepatocytes, sTWEAK administration reduced fat accumulation as demonstrated by the reduction in palmitic acid-induced accumulation of triglyceride and the decreased expression of cluster of differentiation 36 (CD36) and perilipin 1 and 2 (PLIN1 and PLIN2) genes.

conclusionsDecreased sTWEAK concentrations are independently associated with the presence of NAFLD. This is concordant with the observation that TWEAK reduces lipid accumulation in human liver cells.

Indexed as

AdultBody Mass IndexCase-Control StudiesCytokine TWEAKFemaleHepatocytesHumansInsulin ResistanceLiverMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseObesityTriglyceridesCytokine TWEAKTNFSF12 protein, humanTriglycerides

Identifiers

PMID27121253
OpenAlexW2343101658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.